Production and clinical applications of radiopharmaceuticals and medical radioisotopes in Iran
During past 3 decades, nuclear medicine has flourished as vibrant and independent
medical specialty in Iran. Since that time, more than 200 nuclear physicians have been …
medical specialty in Iran. Since that time, more than 200 nuclear physicians have been …
Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with 90Y and 111In for domestic radioimmunotherapy and radioscintigraphy of Non …
N Gholipour, AR Jalilian, A Khalaj… - DARU Journal of …, 2014 - Springer
Background On the basis of results of our previous investigations on 90 Y-DTPA-rituximab
and in order to fulfil national demands to radioimmunoconjugates for radioscintigraphy and …
and in order to fulfil national demands to radioimmunoconjugates for radioscintigraphy and …
SPECT imaging evaluation of 111indium-chelated cetuximab for diagnosing EGFR-positive tumor in an HCT-15-induced colorectal xenograft
BB Shih, YF Chang, CC Cheng, HJ Yang… - Journal of the …, 2017 - journals.lww.com
Background Epidermal growth factor receptor (EGFR) overexpressed in colorectal cancer
(CRC) is a tumor target for developing the anti-tumor theranostic agents. Cetuximab, an anti …
(CRC) is a tumor target for developing the anti-tumor theranostic agents. Cetuximab, an anti …
A review on 90Y-labeled compounds and biomolecules
TH Bokhari, MB Butt, S Hina, M Iqbal, M Daud… - … of Radioanalytical and …, 2017 - Springer
The field of therapeutic nuclear medicine is emerging rapidly as choice of treatment in
oncology and other cellular malignancies. The growth of this branch of nuclear medicine is …
oncology and other cellular malignancies. The growth of this branch of nuclear medicine is …
Preparation & in vitro evaluation of 90Y-DOTA-rituximab
M Kameswaran, U Pandey, A Dash… - Indian Journal of …, 2016 - journals.lww.com
Methods: Rituximab was conjugated with p-SCN-Bn-DOTA at 1: 1 antibody: DOTA molar
ratio. The number of DOTA molecules linked to one molecule of rituximab was determined …
ratio. The number of DOTA molecules linked to one molecule of rituximab was determined …
[PDF][PDF] Optimization of natural rhenium irradiation time to produce compositional radiopharmaceutical
Z Pourhabib, H Ranjbar, A Bahrami Samani… - Iranian Journal of …, 2019 - academia.edu
So far, most of the preclinical and clinical investigations have been made to utilize β-
producing radionuclides, such as 131I, 90Y, 153Sm, 186Re and 188Re [1-3]. Among …
producing radionuclides, such as 131I, 90Y, 153Sm, 186Re and 188Re [1-3]. Among …
金属核素在放射免疫治疗药物中的应用
张君丽， 李洪玉 - 同位素, 2015 - tws.xml-journal.net
恶性肿瘤及其转移瘤的放射免疫靶向治疗越来越受到重视, 已经成为治疗核医学的重要发展方向
之一. 放射免疫治疗药物对肿瘤细胞具有靶向选择性杀伤作用, 可减少对正常非靶组织的损伤 …
之一. 放射免疫治疗药物对肿瘤细胞具有靶向选择性杀伤作用, 可减少对正常非靶组织的损伤 …
[PDF][PDF] Desenvolvimento farmacotécnico de um radioimunoconjugado para terapia de linfoma não-Hodgkin
AVF Massicano - 2016 - pelicano.ipen.br
RESUMO A radioimunoterapia tem se mostrado uma modalidade terapêutica promissora,
especialmente para terapia de tumores hematológicos o que tem impulsionado o …
especialmente para terapia de tumores hematológicos o que tem impulsionado o …
Pharmacotechnical development of a radioimmunoconjugate for non-Hodgkin Lymphoma therapy
AVF Massicano - 2016 - inis.iaea.org
[en] The radioimmunotherapy (RIT) has proven to be a promising therapeutic modality,
especially for therapy of hematological malignancies, which has stimulated the development …
especially for therapy of hematological malignancies, which has stimulated the development …